Skip to content

Study · Randomized controlled trial · n = 71 · 2017

3 results

A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes.

de Wit HM, Vervoort GMM, de Galan BE, Tack CJ

The Netherlands journal of medicine1 Sept 2017Cited by 2 (Europe PMC)

PMID28956786 (opens in a new tab)PepBankPUB-28956786
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialOther

    In patients with type 2 diabetes on insulin, adding liraglutide for 26 weeks cost EUR 699 more per patient than standard insulin therapy.

    In plain wordsIn people with type 2 diabetes on insulin, adding liraglutide for 26 weeks cost EUR 699 more per person than standard insulin therapy.

    Peptide
    Liraglutide
    Outcome
    IncreaseAdditional direct cost per patient
    Study

    n = 71

    Comparator
    Standard insulin therapy
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The additional direct costs of adding liraglutide for 26 weeks were € 699 per patient
    1 context sentence
    Summary · context
    We used data from the 'Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) trial, comparing additional liraglutide (n = 47) and standard insulin therapy (n = 24) during 26 weeks, to calculate the costs associated with different trial periods.
  2. 02HumanRandomized controlled trialOther

    In patients with type 2 diabetes on insulin, adding liraglutide for 26 weeks cost EUR 137 per 1 kg weight loss compared with standard insulin therapy.

    In plain wordsIn people with type 2 diabetes on insulin, adding liraglutide cost EUR 137 for each kilogram lost, compared with standard insulin therapy.

    Peptide
    Liraglutide
    Outcome
    IncreaseAdditional direct cost per kg weight loss
    Study

    n = 71

    Comparator
    Standard insulin therapy
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    or € 137 per 1 kg weight loss, compared with standard therapy.
    1 context sentence
    Summary · context
    We used data from the 'Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) trial, comparing additional liraglutide (n = 47) and standard insulin therapy (n = 24) during 26 weeks, to calculate the costs associated with different trial periods.
  3. 03HumanRandomized controlled trialOther

    In patients with type 2 diabetes on insulin with insulin-associated weight gain, continuing liraglutide only in patients with at least 3% weight loss or at least 60% lower insulin dose at 8 weeks identified 21 of 23 responders, for a total cost of EUR 246.

    In plain wordsIn this cost analysis, an 8-week check of weight loss or insulin dose identified 21 of 23 responders to liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableBest 8-week stopping rule for identifying responders
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The best cost-controlling treatment strategy (identifying 21 of 23 responders, treating four non-responders) was to continue treatment in patients showing ≥ 3% weight loss or ≥ 60% decrease in insulin dose at 8 weeks, with a total cost of € 246 for this t rial period, saving € 453 in case of early discontinuation.
    1 context sentence
    Summary · context
    We used data from the 'Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) trial, comparing additional liraglutide (n = 47) and standard insulin therapy (n = 24) during 26 weeks, to calculate the costs associated with different trial periods.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.